Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

Binhui Biopharmaceutical / Equity Bottom-Up

<ul>
<li>Binhui, a China-based clinical-stage biopharma company, is looking to raise at least USD 100 million via a Hong Kong listing. Huatai, CMB, and BOCI are the joint sponsors.</li>
<li>In this note, we look at the company’s core product, BS001, and key products BS006 and BR003.</li>
<li>We also look at the company’s pre-IPO investors and management team.</li>
</ul>


Binhui, a China-based clinical-stage biopharma company, is looking to raise at least USD 100 million via a Hong Kong listing. Huatai, CMB, and BOCI are the joint sponsors.
In this note, we look at the company’s core product, BS001, and key products BS006 and BR003.
We also look at the company’s pre-IPO investors and management team.


Binhui Biopharm (滨会生物) Pre-IPO Quick Take: High Innovation but Niche Indications

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

Equity Capital Markets

Sany Heavy Industry / Equity Capital Markets

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, Hong Kong and India markets appear to be gearing up for a year end rush.</li>
<li>On the placements front, there were no large deals this week but we did have a look at the upcoming lockup expiries.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, Hong Kong and India markets appear to be gearing up for a year end rush.
On the placements front, there were no large deals this week but we did have a look at the upcoming lockup expiries.


ECM Weekly (27 October 2025)- Sany, Seres, PonyAI, WeRide, CIG, JST, Lenskart, Horizon, CRB

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Binhui Biopharmaceutical (BBP HK)

Binhui Biopharm (滨会生物) Pre-IPO Quick Take: High Innovation but Niche Indications

China's Binhui seeks to raise $100 million through Hong Kong listing with BS001 as its core product, using novel HSV-2 backbone. The company...

Ke Yan, CFA, FRM

ECM Weekly (27 October 2025)- Sany, Seres, PonyAI, WeRide, CIG, JST, Lenskart, Horizon, CRB

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Binhui Biopharm (滨会生物) Pre-IPO Quick Take: High Innovation but Niche Indications

​China's Binhui seeks to raise $100 million through Hong Kong listing with BS001 as its core product, using novel HSV-2 backbone. The company...

Ke Yan, CFA, FRM

ECM Weekly (27 October 2025)- Sany, Seres, PonyAI, WeRide, CIG, JST, Lenskart, Horizon, CRB

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

China's Binhui seeks to raise $100 million through Hong Kong listing with BS001 as its core product, using novel HSV-2 backbone. The company...